查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1775476

组织诊断市场：2025-2030 年预测

Tissue Diagnostics Market - Forecasts from 2025 to 2030
出版日期: | 出版商: Knowledge Sourcing Intelligence | 英文 149 Pages | 商品交期: 最快1-2个工作天内

价格
简介目录

组织诊断市场预计将从 2025 年的 69.29 亿美元成长到 2030 年的 94.09 亿美元，复合年增长率为 6.31%。

慢性病盛行率上升

慢性疾病（尤其是癌症）的日益普及是组织诊断市场的主要驱动力。世界卫生组织 (WHO) 报告称，到 2024 年，慢性疾病将占全球死亡人数的 74%，其中癌症是首要原因。组织诊断涵盖免疫组织化学 (IHC)、原位杂合反应(ISH) 和数位病理学等技术，对于精准诊断和个人化治疗方案至关重要。这些工具能够对组织异常进行详细分析，并支援乳癌和肺癌等疾病的个人化治疗，从而推动对先进诊断解决方案的需求。

老年人口不断增加

全球人口老化是市场成长的主要驱动力。到2024年，60岁及以上人口比例将持续上升，尤其是在已开发地区，这将导致癌症和其他慢性疾病的易感性增加。这些人口结构变化推动了对组织诊断的需求，以促进早期发现和治疗，尤其是在肿瘤学领域，准确的诊断对于改善患者预后至关重要。

积极的政府倡议

世界各国政府正在透过支持性政策和资金来推动组织诊断的发展。 2023年，欧盟津贴用于推动精准医疗，并专注于基于组织的癌症筛检诊断。同样，美国国家癌症研究所也在2024年支持先进诊断技术的研究，以促进市场应用和创新。

诊断创新

技术进步正在改变组织诊断。 2023年，罗氏的 DISCOVERY ULTRA 系统因其自动化 IHC 和 ISH 检测能力而广受欢迎，该系统可在 30 个独立的载玻片抽屉上同时进行手动和自动化实验。该系统支援 FISH 和多重蛋白质 IHC/ISH 等复杂检测，从而提高了诊断准确性。此类创新简化了医院和实验室的工作流程，以满足对快速、准确诊断日益增长的需求。

医院采用率高

由于基于组织的诊断解决方案比传统方法更快、更准确，医院正越来越多地采用此类解决方案。慢性病（尤其是癌症）负担的不断加重，推动了2024年医院对组织诊断的需求。这些解决方案能够加快诊断速度，这对于需要即时干预的疾病（例如肿瘤和心血管疾病）至关重要，从而进一步推动市场成长。

市场限制

高成本

先进组织诊断设备和试剂的高成本限制了其应用，尤其是在开发中地区。截至2024年，儘管数位病理平台等自动化系统效率高，但其成本仍是小型医疗机构的一大障碍。

监理复杂性

不同地区不同的法律规范带来了挑战：2023 年，欧盟严格的核准流程减缓了新诊断工具的推出，增加了製造商的合规成本并减缓了市场扩张。

技术专长要求

有效使用先进的组织诊断技术需要专门的培训，而这在开发中地区往往非常有限。截至2024年，这一差距将继续阻碍亚太地区和非洲地区医疗基础设施仍欠发达地区的广泛应用。

市场区隔分析

依技术

免疫组织化学 (IHC) 因其在癌症诊断中的广泛应用而占据主导地位。 IHC 能够精准侦测分子标记，预计到 2024 年将占市场收益的 40% 以上。数位病理学是成长最快的领域，这得益于人工智慧的整合，以增强影像分析能力。

按用途

癌症诊断正处于领先地位，其中组织诊断对于识别肿瘤类型和指导标靶治疗至关重要。其他应用，例如感染疾病诊断和自体免疫疾病诊断，由于疾病盛行率的上升而正在稳步增长。

按最终用户

医院占比最大，越来越多医院采用组织诊断技术进行快速且准确的检测。 2024年外包趋势将推动诊断实验室规模扩张。

地理洞察力

以美国为首的北美将主导市场，到2024年将占38%的份额。欧洲则以德国和英国为首，这两个国家正专注于早期诊断和筛检计画。亚太地区是一个快速成长的地区，中国和印度将在2023年大力投资诊断基础设施，以应对不断上升的慢性病发病率。

竞争格局

罗氏、雅培、安捷伦科技、BD 和康德乐等主要企业正在推动技术创新。 2023 年，罗氏推出了自动化 IHC 系统，增强了其产品组合；安捷伦则于 2024 年推出了整合 AI 的数位病理解决方案。这些公司利用研发和策略伙伴关係关係来维持市场领先地位。

本报告的主要优点

  • 深刻分析：获得深入的市场洞察，重点关注客户细分、政府政策和社会经济因素、消费者偏好、垂直行业和其他细分市场，涵盖主要地区和新兴地区。
  • 竞争格局：了解主要企业采用的策略策略，并了解正确策略的市场渗透潜力。
  • 市场趋势和驱动因素：探索动态因素和关键市场趋势以及它们将如何影响未来的市场发展。
  • 可行的建议：利用洞察力进行策略决策，在动态环境中开闢新的业务流和收益。
  • 受众范围广：对于新兴企业、研究机构、顾问、中小企业和大型企业来说都是有益且具成本效益的。

它有什么用途？

产业与市场洞察、商业机会评估、产品需求预测、打入市场策略、地理扩张、资本支出决策、监管影响、新产品开发、竞争情报

调查范围

  • 实际数据为2022年至2024年，预测数据为2025年至2030年
  • 成长机会、挑战、供应链前景、法律规范与趋势分析
  • 竞争定位、策略和市场占有率分析
  • 收益成长和预测细分市场和区域分析（包括国家）
  • 公司概况（策略、产品、财务、主要发展等）

目录

第一章执行摘要

第二章市场概述

  • 市场概览
  • 市场定义
  • 调查范围
  • 市场区隔

第三章 经营状况

  • 市场驱动因素
  • 市场限制
  • 市场机会
  • 波特五力分析
  • 产业价值链分析
  • 政策法规
  • 策略建议

第四章 技术展望

第 5 章：组织诊断市场（按产品）

  • 介绍
  • 耗材
    • 抗体
    • 套件
    • 探测
    • 试剂
  • 装置
    • 幻灯片扫描仪
    • 玻片染色系统
    • 组织微阵列
    • 组织处理系统
    • 其他的

第六章：组织诊断市场（依技术）

  • 介绍
  • 数位病理学
  • 免疫组织化学（IHC）
  • 原位杂交（ISH）
  • 其他的

第七章：组织诊断市场（按应用）

  • 介绍
  • 乳癌
  • 子宫颈癌
  • 大肠直肠癌
  • 胃癌
  • 肺癌
  • 其他的

第 8 章：组织诊断市场（依最终使用者）

  • 介绍
  • 合约研究组织（CRO）
  • 医院
  • 诊断中心
  • 其他的

第 9 章：按地区分類的组织诊断市场

  • 介绍
  • 北美洲
    • 按产品
    • 依技术
    • 按用途
    • 按最终用户
    • 按国家
      • 美国
      • 加拿大
      • 墨西哥
  • 南美洲
    • 按产品
    • 依技术
    • 按用途
    • 按最终用户
    • 按国家
      • 巴西
      • 阿根廷
      • 其他的
  • 欧洲
    • 按产品
    • 依技术
    • 按用途
    • 按最终用户
    • 按国家
      • 德国
      • 法国
      • 英国
      • 西班牙
      • 其他的
  • 中东和非洲
    • 按产品
    • 依技术
    • 按用途
    • 按最终用户
    • 按国家
      • 沙乌地阿拉伯
      • 阿拉伯聯合大公国
      • 其他的
  • 亚太地区
    • 按产品
    • 依技术
    • 按用途
    • 按最终用户
    • 按国家
      • 中国
      • 印度
      • 日本
      • 韩国
      • 印尼
      • 其他的

第十章竞争格局及分析

  • 主要企业和策略分析
  • 市场占有率分析
  • 合併、收购、协议和合作
  • 竞争对手仪表板

第十一章：公司简介

  • Abbott Laboratories
  • Agilent Technologies, Inc.
  • Becton Dickinson
  • BioGenex
  • Cardinal Health
  • Danaher
  • F. Hoffmann-La Roche Ltd
  • Medtronic
  • Merck KgaA
  • Thermo Fisher Scientific Inc.

第十二章 附录

  • 货币
  • 先决条件
  • 基准年和预测年时间表
  • 相关人员的主要利益
  • 调查方法
  • 简称
简介目录
Product Code: KSI061610034

The tissue diagnostics market is expected to grow from USD 6.929 billion in 2025 to USD 9.409 billion in 2030, at a CAGR of 6.31%.

Rising Prevalence of Chronic Diseases

The increasing incidence of chronic diseases, particularly cancer, is a primary driver of the tissue diagnostics market. In 2024, the World Health Organization reported that chronic diseases accounted for 74% of global deaths, with cancer being a leading cause. Tissue diagnostics, encompassing techniques like immunohistochemistry (IHC), in situ hybridization (ISH), and digital pathology, are critical for accurate diagnosis and personalized treatment planning. These tools enable detailed analysis of tissue abnormalities, supporting tailored therapies for conditions like breast and lung cancer, driving demand for advanced diagnostic solutions.

Growing Geriatric Population

The global aging population is significantly boosting market growth. In 2024, the proportion of individuals aged 60 and older continued to rise, particularly in developed regions, increasing susceptibility to cancers and other chronic conditions. This demographic shift has heightened the need for tissue diagnostics to facilitate early detection and treatment, especially in oncology, where precise diagnostics are essential for improving patient outcomes.

Favorable Government Initiatives

Governments worldwide are promoting tissue diagnostics through supportive policies and funding. In 2023, the European Union allocated grants to advance precision medicine, emphasizing tissue-based diagnostics for cancer screening. Similarly, U.S. initiatives under the National Cancer Institute in 2024 supported research into advanced diagnostic technologies, fostering adoption and innovation in the market.

Diagnostic Innovations

Technological advancements are transforming tissue diagnostics. In 2023, Roche's DISCOVERY ULTRA system gained traction for its ability to automate IHC and ISH assays, enabling simultaneous manual and automated experiments with 30 independent slide drawers. This system supports complex assays like FISH and multiplex protein IHC/ISH, enhancing diagnostic accuracy. Such innovations streamline workflows in hospitals and laboratories, meeting the growing demand for rapid, precise diagnostics.

High Hospital Adoption

Hospitals are increasingly adopting tissue-based diagnostic solutions due to their speed and accuracy compared to conventional methods. In 2024, the rising burden of chronic diseases, particularly cancer, drove hospital demand for tissue diagnostics. These solutions enable faster diagnosis, critical for conditions requiring immediate intervention, such as oncology and cardiovascular diseases, further propelling market growth.

Market Restraints

High Costs

The high cost of advanced tissue diagnostic instruments and reagents limits adoption, particularly in developing regions. In 2024, the cost of automated systems like digital pathology platforms remained a barrier for smaller healthcare facilities, despite their efficiency.

Regulatory Complexity

Diverse regulatory frameworks across regions pose challenges. In 2023, stringent approval processes in the EU delayed the rollout of new diagnostic tools, increasing compliance costs for manufacturers and slowing market expansion.

Technical Expertise Requirements

The effective use of advanced tissue diagnostics requires specialized training, which is often limited in developing regions. In 2024, this gap hindered adoption in parts of Asia-Pacific and Africa, where healthcare infrastructure is still evolving.

Market Segmentation Analysis

By Technology

Immunohistochemistry (IHC) dominates due to its widespread use in cancer diagnostics. In 2024, IHC accounted for over 40% of market revenue, driven by its precision in detecting molecular markers. Digital pathology is the fastest-growing segment, fueled by AI integration for enhanced image analysis.

By Application

Cancer diagnosis leads, with tissue diagnostics critical for identifying tumor types and guiding targeted therapies. Other applications, like infectious and autoimmune disease diagnostics, are growing steadily due to rising disease prevalence.

By End-User

Hospitals hold the largest share, driven by high adoption of tissue diagnostics for rapid and accurate testing. Diagnostic laboratories are expanding, supported by outsourcing trends in 2024.

Geographical Insights

North America, led by the U.S., dominates the market, holding a 38% share in 2024, driven by advanced healthcare infrastructure and a high cancer burden. Europe follows, with Germany and the UK leading due to strong focus on early diagnosis and screening programs. Asia-Pacific is the fastest-growing region, with China and India investing heavily in diagnostic infrastructure in 2023 to address rising chronic disease rates.

Competitive Landscape

Key players, including Roche, Abbott Laboratories, Agilent Technologies, BD, and Cardinal Health, drive innovation. In 2023, Roche enhanced its portfolio with automated IHC systems, while Agilent introduced AI-integrated digital pathology solutions in 2024. These companies leverage R&D and strategic partnerships to maintain market leadership.

Key Benefits of this Report:

  • Insightful Analysis: Gain detailed market insights covering major as well as emerging geographical regions, focusing on customer segments, government policies and socio-economic factors, consumer preferences, industry verticals, and other sub-segments.
  • Competitive Landscape: Understand the strategic maneuvers employed by key players globally to understand possible market penetration with the correct strategy.
  • Market Drivers & Future Trends: Explore the dynamic factors and pivotal market trends and how they will shape future market developments.
  • Actionable Recommendations: Utilize the insights to exercise strategic decisions to uncover new business streams and revenues in a dynamic environment.
  • Caters to a Wide Audience: Beneficial and cost-effective for startups, research institutions, consultants, SMEs, and large enterprises.

What do businesses use our reports for?

Industry and Market Insights, Opportunity Assessment, Product Demand Forecasting, Market Entry Strategy, Geographical Expansion, Capital Investment Decisions, Regulatory Framework & Implications, New Product Development, Competitive Intelligence

Report Coverage:

  • Historical data from 2022 to 2024 & forecast data from 2025 to 2030
  • Growth Opportunities, Challenges, Supply Chain Outlook, Regulatory Framework, and Trend Analysis
  • Competitive Positioning, Strategies, and Market Share Analysis
  • Revenue Growth and Forecast Assessment of segments and regions including countries
  • Company Profiling (Strategies, Products, Financial Information, and Key Developments among others.

Market Segmentation:

By Product

  • Consumables
  • Antibodies
  • Kits
  • Probes
  • Reagents
  • Instruments
  • Slide Scanners
  • Slide Staining Systems
  • Tissue Microarrays
  • Tissue Processing Systems
  • Others

By Technology

  • Digital Pathology
  • Immunohistochemistry (IHC)
  • In Situ Hybridization (ISH)
  • Others

By Application

  • Breast cancer
  • Cervical cancer
  • Colorectal cancer
  • Gastric cancer
  • Lung cancer
  • Others

By End-Users

  • Contract Research Organizations (CROs)
  • Hospitals
  • Diagnostic Centers
  • Others

By Geography

  • North America
  • USA
  • Canada
  • Mexico
  • South America
  • Brazil
  • Argentina
  • Others
  • Europe
  • Germany
  • France
  • United Kingdom
  • Italy
  • Others
  • Middle East and Africa
  • UAE
  • Saudi Arabia
  • Others
  • Asia Pacific
  • Japan
  • China
  • South Korea
  • India
  • Others

TABLE OF CONTENTS

1. EXECUTIVE SUMMARY

2. MARKET SNAPSHOT

  • 2.1. Market Overview
  • 2.2. Market Definition
  • 2.3. Scope of the Study
  • 2.4. Market Segmentation

3. BUSINESS LANDSCAPE

  • 3.1. Market Drivers
  • 3.2. Market Restraints
  • 3.3. Market Opportunities
  • 3.4. Porter's Five Forces Analysis
  • 3.5. Industry Value Chain Analysis
  • 3.6. Policies and Regulations
  • 3.7. Strategic Recommendations

4. TECHNOLOGICAL OUTLOOK

5. TISSUE DIAGNOSTICS MARKET BY PRODUCT

  • 5.1. Introduction
  • 5.2. Consumables
    • 5.2.1. Antibodies
    • 5.2.2. Kits
    • 5.2.3. Probes
    • 5.2.4. Reagents
  • 5.3. Instruments
    • 5.3.1. Slide Scanners
    • 5.3.2. Slide Staining System
    • 5.3.3. Tissue Microarrays
    • 5.3.4. Tissue Processing System
    • 5.3.5. Others

6. TISSUE DIAGNOSTICS MARKET BY TECHNOLOGY

  • 6.1. Introduction
  • 6.2. Digital Pathology
  • 6.3. Immunohistochemistry (IHC)
  • 6.4. In Situ Hybridization (ISH)
  • 6.5. Others

7. TISSUE DIAGNOSTICS MARKET BY APPLICATION

  • 7.1. Introduction
  • 7.2. Breast Cancer
  • 7.3. Cervical Cancer
  • 7.4. Colorectal Cancer
  • 7.5. Gastric Cancer
  • 7.6. Lung Cancer
  • 7.7. Others

8. TISSUE DIAGNOSTICS MARKET BY END-USER

  • 8.1. Introduction
  • 8.2. Contract Research Organization (CRO)
  • 8.3. Hospitals
  • 8.4. Diagnostics Centers
  • 8.5. Others

9. TISSUE DIAGNOSTICS MARKET BY GEOGRAPHY

  • 9.1. Introduction
  • 9.2. North America
    • 9.2.1. By Product
    • 9.2.2. By Technology
    • 9.2.3. By Application
    • 9.2.4. By End-User
    • 9.2.5. By Country
      • 9.2.5.1. USA
      • 9.2.5.2. Canada
      • 9.2.5.3. Mexico
  • 9.3. South America
    • 9.3.1. By Product
    • 9.3.2. By Technology
    • 9.3.3. By Application
    • 9.3.4. By End-User
    • 9.3.5. By Country
      • 9.3.5.1. Brazil
      • 9.3.5.2. Argentina
      • 9.3.5.3. Others
  • 9.4. Europe
    • 9.4.1. By Product
    • 9.4.2. By Technology
    • 9.4.3. By Application
    • 9.4.4. By End-User
    • 9.4.5. By Country
      • 9.4.5.1. Germany
      • 9.4.5.2. France
      • 9.4.5.3. United Kingdom
      • 9.4.5.4. Spain
      • 9.4.5.5. Others
  • 9.5. Middle East and Africa
    • 9.5.1. By Product
    • 9.5.2. By Technology
    • 9.5.3. By Application
    • 9.5.4. By End-User
    • 9.5.5. By Country
      • 9.5.5.1. Saudi Arabia
      • 9.5.5.2. UAE
      • 9.5.5.3. Others
  • 9.6. Asia Pacific
    • 9.6.1. By Product
    • 9.6.2. By Technology
    • 9.6.3. By Application
    • 9.6.4. By End-User
    • 9.6.5. By Country
      • 9.6.5.1. China
      • 9.6.5.2. India
      • 9.6.5.3. Japan
      • 9.6.5.4. South Korea
      • 9.6.5.5. Indonesia
      • 9.6.5.6. Others

10. COMPETITIVE ENVIRONMENT AND ANALYSIS

  • 10.1. Major Players and Strategy Analysis
  • 10.2. Market Share Analysis
  • 10.3. Mergers, Acquisitions, Agreements, and Collaborations
  • 10.4. Competitive Dashboard

11. COMPANY PROFILES

  • 11.1. Abbott Laboratories
  • 11.2. Agilent Technologies, Inc.
  • 11.3. Becton Dickinson
  • 11.4. BioGenex
  • 11.5. Cardinal Health
  • 11.6. Danaher
  • 11.7. F. Hoffmann-La Roche Ltd
  • 11.8. Medtronic
  • 11.9. Merck KgaA
  • 11.10. Thermo Fisher Scientific Inc.

12. APPENDIX

  • 12.1. Currency
  • 12.2. Assumptions
  • 12.3. Base and Forecast Years Timeline
  • 12.4. Key benefits for the stakeholders
  • 12.5. Research Methodology
  • 12.6. Abbreviations